Test diagnostici

1. RCP VITRAKVI
2. VITRAKVI Gazzetta Ufficiale, Settembre 2021.
3. Hechtman JF, Benayed R, Hyman DM, et al. Pan-trk immunohistochemistry is an efficient and reliable screen for the detection of NTRK fusions. Am J Surg Pathol. 2017;41(11):1547-1551.
4. Su D, Zhang D, Chen K, et al. High performance of targeted next generation sequencing on variance detection in clinical tumor specimens in comparison with current conventional methods. J Exp Clin Cancer Res. 2017;36(1):1-12.
5. Lih C-J, Harrington RD, Sims DJ, et al. Analytical validation of the next-generation sequencing assay for a nationwide signal-finding clinical trial: Molecular Analysis for Therapy Choice clinical trial. J Mol Diagn. 2017;19(2):313-327.
6. Park HS, Park S-J, Kim JY, et al. Next-generation sequencing of BRCA1/2 in breast cancer patients: potential effects on clinical decisionmaking using rapid, high-accuracy genetic results. Ann Surg Treat Res. 2017;92(5):331-339.
7. Fox AJ, Hiemenz MC, Lieberman DB. Next generation sequencing for the detection of actionable mutations in solid and liquid tumors. J Vis Exp. 2016;115:e52758. doi:10.3791/52758.
8. Boland GM, Piha-Paul SA, Subbiah V, et al. Clinical next generation sequencing to identify actionable aberrations in a phase I program. Oncotarget. 2015;6(24):20099-20110.
9. Ozsolak F, Milos PM. RNA sequencing: advances, challenges and opportunities. Nat Rev Genet. 2011;12(2):87-98.
10. Murphy DA, Ely HA, Shoemaker R, et al. Detecting gene rearrangements in patient populations through a 2-step diagnostic test comprised of rapid IHC enrichment followed by sensitive next-generation sequencing. Appl Immunohistochem Mol Morphol. 2017;25(7):513-523.
11. Rogers T-M, Arnau GM, Ryland GL, et al. Multiplexed transcriptome analysis to detect ALK, ROS1 and RET rearrangements in lung cancer. Sci Rep. 2017;7:42259. doi:10.1038/srep42259.
12. Bourgeois JM, Knezevich SR, Mathers JA, Sorensen PHB. Molecular detection of the ETV6-NTRK3 gene fusion differentiates congenital fibrosarcoma from other childhood spindle cell tumors. Am J Surg Pathol. 2000;24(7):937-946.
13. Knezevich SR, McFadden DE, Tao W, Lim JF, Sorensen PHB. A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma. Nat Genet. 1998;18(2):184-187.
14. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®) for Non-Small Cell Lung Cancer–V.6.2020. ©National Comprehensive Cancer Network, Inc. 2020. All rights reserved. Accessed September 14, 2020. To view the most recent and comprehensive version of the NCCN Guidelines, go online to NCCN.org.
15. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®) for Colon Cancer–V.4.2020. ©National Comprehensive Cancer Network, Inc. 2020. All rights reserved. Accessed September 14, 2020. To view the most recent and comprehensive version of the NCCN Guidelines, go online to NCCN.org.
16. Jiao X, Lokker A, Snider J, et al. Co-occurrence of NTRK fusions with other genomic biomarkers in cancer patients. Poster presented at: European Society for Medical Oncology Congress; September 27-October 1, 2019; Barcelona, Spain.
17. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®) for Thyroid Carcinoma–V.2.2020. ©National Comprehensive Cancer Network, Inc. 2020. All rights reserved. Accessed September 14, 2020. To view the most recent and comprehensive version of the NCCN Guidelines, go online to NCCN.org.
18. Hsiao SJ, Zehir A, Sireci AN, Aisner DL. Detection of tumor NTRK gene fusions to identify patients who may benefit from tyrosine kinase (TRK) inhibitor therapy. J Mol Diagn. 2019;21(4):553-571.
19. Solomon JP, Benayed R, Hechtman JF, Ladanyi M. Identifying patients with NTRK fusion cancer. Ann Oncol. 2019;30(suppl 8):viii16-viii22.
20. Bishop JA, Yonescu R, Batista D, Eisele DW, Westra WH. Most non-parotid “acinic cell carcinomas” represent mammary analogue secretory carcinomas. Am J Surg Pathol. 2013;37(7):1053-1057.
21. Rubin BP, Chen C-J, Morgan TW, et al. Congenital mesoblastic nephroma t(12;15) is associated with ETV6-NTRK3 gene fusion. Am J Pathol. 1998;153(5):1451-1458.
22. Tognon C, Knezevich SR, Huntsman D, et al. Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma. Cancer Cell. 2002;2(5):367-376.

^a Gli anticorpi pan-TRK sono in grado di rilevare le proteine TRK A, B e C tra le proteine di fusione sia wild-type che chimeriche. Pertanto, l’espressione proteica può non essere correlata a una fusione genica.¹

• ALK: chinasi del linfoma anaplastico; 
• BRAF: proto-oncogene B-Raf; 
• EGFR: recettore del fattore di crescita epidermico; 
• ETV6: ETS variante 6; 
• FISH: ibridazione fluorescente in situ; 
• HER2: recettore del fattore di crescita epidermico umano 2; 
• IFS: fibrosarcoma infantile; 
• IHC: immunoistochimica; 
• NGS: sequenziamento di nuova generazione; 
• NTRK: recettore tirosin-chinasico neurotrofico; 
• PDGFRA: recettore alfa del fattore di crescita derivato dalle piastrine; 
• ROS1: oncogene c-ros 1.
• RT-PCR: reazione a catena della polimerasi inversa; 
• TRK: recettore della tropomiosina chinasi. 

Questa presentazione deve essere usata solo nei mercati che accettano dati valutati dagli sperimentatori.

• CMN: nefroma mesoblastico congenito; 
• EGFR: recettore del fattore di crescita epidermico; \
• IFS: fibrosarcoma infantile; 
• KIT: recettore tirosin-chinasico del proto-oncogene KIT; 
• KRAS: omologo dell’oncogene virale del sarcoma del ratto di Kirsten; 
• MASC: carcinoma secretorio simil-mammario; 
• MSI-H: instabilità dei microsatelliti-elevata; 
• NRAS: omologo dell’oncogene virale RAS del neuroblastoma;